Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · March 19, 2023

Effect of Rivaroxaban vs Enoxaparin on MACEs and Bleeding Risk in the Acute Phase of Acute Coronary Syndrome

JAMA Network Open


Additional Info

JAMA Network Open
Effect of Rivaroxaban vs Enoxaparin on Major Cardiac Adverse Events and Bleeding Risk in the Acute Phase of Acute Coronary Syndrome: The H-REPLACE Randomized Equivalence and Noninferiority Trial
JAMA Netw Open 2023 Feb 01;6(2)e2255709, S Zhou, Y Xiao, C Zhou, Z Zheng, W Jiang, Q Shen, C Zhu, H Pan, C Liu, G Zeng, L Ge, Y Zhang, Z Ouyang, G Fu, G Pan, F Chen, L Huang, Q Liu

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading